Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Mull

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Medical Cases|August 26, 2021
Perioperative Implications of VapingAmogha Krishna, Wana Mathieu, Eric Mull, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitorsSharad Verma, Dhanapalan Nagarathnam, Jianxing Shao, et al.
Journal of Medicinal Chemistry|November 23, 2020
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionLi-Qiang Sun, Eric Mull, Stanley D'Andrea, et al.
Journal of Medicinal Chemistry|August 27, 2016
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily DosingLi-Qiang Sun, Eric Mull, Barbara Zheng, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Medical Cases|August 26, 2021
Perioperative Implications of VapingAmogha Krishna, Wana Mathieu, Eric Mull, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitorsSharad Verma, Dhanapalan Nagarathnam, Jianxing Shao, et al.
Journal of Medicinal Chemistry|November 23, 2020
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionLi-Qiang Sun, Eric Mull, Stanley D'Andrea, et al.
Journal of Medicinal Chemistry|August 27, 2016
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily DosingLi-Qiang Sun, Eric Mull, Barbara Zheng, et al.
Pageof 1